Conference Call with Epigral Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Specialty Chemicals company Epigral announced Q3FY25 results Q3FY25 Financial Highlights: Revenue stood at Rs 649 crore, growth of 37% YoY on account volume growth from Derivative products. Revenue contribution from Derivatives & Specialty business increased to 50% in Q3FY25 vs 47% in Q3FY24. EBITDA grew by 49% to Rs 183 crore vs Rs 123 crore in Q3FY24. EBIDTA margin stood at 28% vs 26% in Q3FY24. o PAT jumped by 110% to Rs 104 crore. PAT margin grew to 16% vs 10% in Q3FY24. ROCE grew to 25% as on 31st December 2024 vs 18% as on 31st December 2023. Net Debt / EBITDA significantly reduced to 0.8x as on 31st December 2024 vs 1.96x as on 31st December 2023 on account of improvement TTM EBITDA and reduction in Net Debt. Maulik Patel, Chairman and Managing Director, Epigral said: “Epigral’s revenue grew by 37% in Nine months of FY25 on account 15% growth in sales volume from Derivatives business and high value products. The diversification strategy of our company has played a key role in witnessing consistent and stable growth in this subdued demand scenario. Revenue contribution from Derivatives business stood at 54% for 9MFY25 vs 44% in 9MFY24” “Epigral is a growth-focused company and the volume in FY25 grew on account of various projects commissioned in the recent past. These projects will further contribute in FY26 along with a contribution from Chlorotoluenes Value Chain, it is expected to get commissioned in the current quarter. Further we are expanding and doubling our CPVC Resin and Epichlorohydrin capacity and we expect volume contribution from these projects from FY27 onwards. At Epigral we are moving in line with our strategy to grow consistently along with strengthening our integrated complex and catering to diversified industries for creating value for our stakeholders.” Result PDF